231TiP - KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Oesophageal Cancer
Gastric Cancer
Cancer Immunology and Immunotherapy
Presenter Eric van Cutsem
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors E. van Cutsem1, C.S. Fuchs2, A.E. Denker3, J. Tabernero4, A. Ohtsu5, B. Lam3, M. Koshiji3, Y. Bang6
  • 1Gastroenterology/digestive Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 - Leuven/BE
  • 2Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston/US
  • 3Clinical Oncology, Merck & Co., Inc., Kenilworth/US
  • 4Medical Oncology Service, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5Exploratory Oncology Research And Clinical Trial Center, National Cancer Center Hospital East, JP-277-8577 - Kashiwa/JP
  • 6Dept Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR

Abstract

Background

Pembrolizumab (pembro) is a humanized monoclonal antibody against PD-1 that prevents it from interacting with its ligands, PD-L1 and PD-L2. In the phase 1 KEYNOTE-012 trial of patients (pts) with PD-L1+ metastatic gastric cancer, pembro showed an acceptable safety profile and promising antitumor activity. The multicohort, phase 2 KEYNOTE-059 (NCT02335411) trial was designed to further evaluate pembro in pts with advanced gastric cancer.

Trial design

Key eligibility criteria are age ≥18 y, relapsed or metastatic gastric or gastroesophageal junction adenocarcinoma, measurable disease, ECOG PS 0-1, no active autoimmune disease, no prior chemotherapy within 2 wk of first dose, and no active brain metastases. PD-L1 status will be assessed in all pts via IHC. Cohort 1 (C1) will include up to 180 pts with any PD-L1 status who progressed on ≥2 prior chemotherapy regimens that included a fluoropyrimidine and a platinum doublet; HER2+ pts must have received trastuzumab. Cohort 2 (C2) will enroll ∼12 Asian and ∼6 non-Asian, treatment-naive, HER2– pts of any PD-L1 status. Cohort 3 (C3) will include ∼25 treatment-naive pts with HER2–/PD-L1+ tumors. In C1 and C3, pts will receive pembro 200 mg Q3W. In C2, pts will receive pembro 200 mg Q3W + infusional 5-FU or capecitabine and 6 cycles of cisplatin. Treatment may continue for up to 24 mo or until progression, intolerable toxicity, or investigator decision. Discontinuation before 24 mo is permitted for pts who have CR and receive ≥24 wk of treatment and ≥2 doses beyond initial response. Eligible pts may continue treatment beyond initial RECIST-defined progression. AEs will be collected and graded per NCI CTCAE v4.0. Response will be assessed at wk 9 and every 6 wk thereafter per RECIST v1.1 and RECIST v1.1 adapted to account for the unique response patterns that may be observed with immunotherapy. ORR per RECIST v1.1 by central review is the primary efficacy end point for C1 and C3; safety and tolerability of the combination is the primary end point for C2. Secondary end points include PFS, OS, DCR, and duration of response. Enrollment in KEYNOTE-059 was initiated in February 2015 and will continue until up to 270 pts are enrolled across all cohorts.

Clinical trial identification

NCT02335411

Disclosure

E. Van Cutsem: consultant or advisory role: Merck. A.E. Denker: employee of and holds stock in Merck & Co., Inc. J. Tabernero: consultant/advisor for Amgen, Inclone, Lilly, Merck Serono, Merck & Co., Inc., Millennium, Novartis, Roche, Sanofi, Celgene, Chugai and Taiho. B. Lam: currently employed by Merck & Co., Inc.; previously employed by Kaiser Permanente/TPMG. M. Koshiji: currently employed at Merck & Co., Inc. Previously employed at Lilly; current Lilly stock owner. All other authors have declared no conflicts of interest.